PU21.03	Assessment of crosslinker suitability for fusion peptide conjugates as priming immunogens for an HIV-1 vaccine	Publication Only	Novel vaccine and other prevention approaches
PE16.04	Assessing the use of surveillance data to estimate reductions in HIV incidence achieved by combination HIV prevention programs: a mathematical modelling study	E-poster	Implementation science, including structural interventions, PrEP & VMMC
PE01.38	Assessing longitudinal patterns of depressive symptoms and the influence of symptom trajectories on PrEP persistence among adolescent girls in HPTN 082	E-poster	Behavioural and social science research
PE16.38LB	Applying statistical control processes to characterize the variations in occurrence of adverse events in VMMC delivery in Zimbabwe	E-poster	Implementation science, including structural interventions, PrEP & VMMC
OA09.04	Applying insights from HIV to guide the development of a T-cell vaccine for SARS-CoV-2	Oral Abstract Session	COVID research: Applying lessons from HIV prevention to SARS CoV-2
PE08.09LB	Anti-HPV and anti-HSV activity in rectal enema effluents collected from subjects receiving PC-1005: a dual compartment multipurpose prevention technology formulation	E-poster	Delivery technologies: novel approaches, formulation and multi-purpose
OA09.02	Anti-Env antibody-independent protection of repeated intrarectal low-dose SIVmac239 challenges in rhesus macaques by vaccination inducing Gag/Vif-specific CD8+ T but not CD4+ T cells	Oral Abstract Session	Mucosal immunity
PE08.05	Anti-CCR5 siRNA-loaded polymeric nanoparticles for topical pre-exposure prophylaxis	E-poster	Delivery technologies: novel approaches, formulation and multi-purpose
PE02.03	Antibody-Antigen Distance of Broadly Neutralizing HIV-1 Antibodies Correlates with Glycan-Shield Coverage of HIV-1 Envelope Trimer	E-poster	Broadly neutralizing antibodies
OA08.01	Antibody isotype switching as a mechanism to counter HIV neutralization escape	Oral Abstract Session	Humoral immunity